Insights

1. What Patent Use Codes Are and Why They Cost the Healthcare System $3.5 Billion per Year A patent use […]

Why Patent Data Outperforms Every Other Pharma Signal A company’s balance sheet is a photograph of last quarter. Its clinical

1. The Market Imperative: Biologics Cost 46% of U.S. Drug Spend at Less Than 2% of Volume Biologic drugs generated

Section 1: The Patent as a Balance Sheet Asset A pharmaceutical patent is not a legal formality. It is the

Introduction: The End of the Free Pricing Era The pharmaceutical industry has long operated under a unique social contract: invest

1. Why Extrapolation Is the Most Valuable Two Words in Biosimilar Development Biologics occupy a peculiar place in the pharmaceutical

1. Introduction: The Economic Imperative of Valuation in Life Sciences The valuation of pharmaceutical and biotechnology entities constitutes one of

The New Economic Reality of Drug Manufacturing The days of selecting a Contract Development and Manufacturing Organization on the lowest

Introduction: The Market Paradox That Drives Every Deal The global generic drug industry has spent the last decade locked in